元胡止痛胶囊

Search documents
天目药业:全资子公司获药品再注册批准通知书
Xin Lang Cai Jing· 2025-09-22 08:59
Core Viewpoint - The company has received a drug re-registration approval from the Anhui Provincial Drug Administration, which is crucial for the stability and continuity of its drug production and sales qualifications [1] Group 1 - The re-registration involves multiple products including Liuwei Dihuang Wan, Yuanhu Zhitong Capsules, and Qiju Dihuang Wan, with the approval valid until November 2030 [1] - This approval is expected to positively impact the company's future production, sales, and promotion efforts [1] - The company commits to strict compliance with production requirements to ensure product quality and provide high-quality products to the market [1]